The global in vitro lung model market comprises three-dimensional tissue culture models and microfluidic lung models. Three-dimensional tissue culture models such as co-cultures consisting of primary lung epithelial and endothelial cells provide a close lung mimic. However, advanced microfluidic lung models with integrated engineering approaches allow the recapitulation of complex, multicellular lung-on-chip and tissue-on-chip systems containing physiological breathing motions. The in vitro lung models find wide applications in drug discovery and development, basic research, toxicology testing, 3D tissue engineering, and disease pathology studies.
The Global in vitro lung model market is estimated to be valued at US$ 245.0 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global in vitro lung market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited.
The Global In Vitro Lung Model Market Size is expected to witness significant growth owing to increasing demand for human-based predictive lung disease models for drug discovery and development. Lung diseases pose a huge disease burden globally. In vitro lung models are playing a critical role in advancing precision medicine approaches for developing safe and effective therapies for lung diseases.
Furthermore, investments in research infrastructure and initiatives by research bodies and major pharmaceutical companies for developing human-relevant preclinical models for accelerating drug development are contributing to the expansion of the global in vitro lung model market. Besides drug R&D, the market is also gaining from the increasing applications of in vitro lung models in basic and applied biomedical research.
Market drivers
Rising drug development R&D activities in the pharmaceutical and biotechnology industries is a major factor driving the global in vitro lung model market. The integration of 3D tissue engineering and microfluidic techniques has enabled the development of advanced human lung-on-chip models with improved physiological relevance for preclinical drug testing and evaluation. This is reducing reliance on animal models, saving development costs and improving drug candidate success rates. This is expected to significantly boost the adoption of in vitro lung models in the coming years.
Get more insights on This Topic- Global In Vitro Lung Model Market